Trials / Active Not Recruiting
Active Not RecruitingNCT04722146
A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
A Multi-arm Phase 1b Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to characterize the safety and tolerability of teclistamab when administered in different combination regimen and to identify the optimal dose(s) of teclistamab combination regimens.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Teclistamab | Participants will receive teclistamab. |
| DRUG | Daratumumab | Participants will receive daratumumab. |
| DRUG | Pomalidomide | Participants will receive pomalidomide. |
| DRUG | Lenalidomide | Participants will receive lenalidomide. |
| DRUG | Bortezomib | Participants will receive bortezomib. |
| DRUG | Nirogacestat | Participants will receive nirogacestat. |
Timeline
- Start date
- 2021-03-12
- Primary completion
- 2027-04-07
- Completion
- 2027-10-05
- First posted
- 2021-01-25
- Last updated
- 2026-04-13
Locations
27 sites across 5 countries: United States, Australia, Belgium, France, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04722146. Inclusion in this directory is not an endorsement.